| abstract |
FIELD: biotechnology, medicine, diagnosis, in particular monoclonal antibody production. n SUBSTANCE: monoclonal antibody which selectively binds to DR5 TRAIL-receptor and doesn't bind to DR4, DcR1 or DcR2 TRAIL-receptor is obtained by hybridome technology. Antibody is detected by testing in vitro system based on ability thereof to induce death of DR5 expressing target cells in dissolved form at concentration less than 1 mum/ml, and in vivo system based on ability thereof to display tumoricide activity in relates to DR5 expressing target cells. Monoclonal body in reproduced by transgenic technologies including cultivation of recombinant E.coli strain-producers. Antibody in therapeutically effective amounts is used in therapy of inflammation, autoimmune and apoptosis-associated diseases, as well as in complex therapy of cancer patients. Said monoclonal antibody in concentration of less than 1 mum/ml makes it possible to selectively induce death or proliferation of DR5 expressing target cells. n EFFECT: new antibody selective to apoptosis inducing ligand receptor. n 105 cl, 154 dwg, 4 tbl, 26 ex |